课题基金 / 基金详情

A Novel High Throughput Assay for Ion Channel Modulators

A Novel High Throughput Assay for Ion Channel Modulators
离子通道调制器的新型高通量测定
批准号:
7120669
负责人:
Barbara A Wible
金额:
$24.77万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-02-01 至 2007-07-31

项目摘要

项目成果

Barbara A Wible的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):离子通道包括10-20%的已知药物靶标,用于治疗各种疾病,包括心律失常、中风、高血压、心力衰竭、哮喘、囊性纤维化、癫痫、偏头痛、精神障碍、肌肉营养不良和癌症。虽然离子通道提供了重要的治疗靶点,但它们往往是不受欢迎的药物相互作用的焦点,导致潜在的严重副作用。心脏钾通道HERG是最常见的不良药物相互作用的靶点;阻断HERG可使个体易于发生心律失常、长QT综合征和心脏性猝死。FDA建议所有正在考虑用于研究新药应用(IND)的药物在临床前研究中测试它们对HERG钾通道的影响。由于药物开发成本的增加,制药公司在过程的早期阶段测试其化合物的HERG责任是至关重要的。最近的证据表明,药物诱导的HERG敏感性不仅可以直接阻断该通道,还可以通过抑制HERG通道从其细胞内合成部位到细胞表面的运动而产生。这种转运抑制导致细胞表面的功能通道较少。三氧化二砷和五烷双胺,这两种现在临床上使用的药物,都是以这种方式起作用的,并与长QT综合征有关。目前确定HERG责任的方法中没有一种能够检测到贩运抑制因素。ChanXpress,Inc.为Herg责任开发了一种新的安全屏幕,这是现有的最全面的。它使用一种专利技术检测通道阻滞剂和贩运抑制剂,该技术使用基于抗体的化学发光分析来监测HERG通道的表面表达。在第二阶段,我们将编制一个包含880种化合物的Herg风险数据库,其中包括Herg-Lite筛选结果以及膜片钳和蛋白质印迹数据。我们将在ChanXpress上实现Herg-Lite检测的自动化,以便能够以比目前可用的更高的吞吐量提供给更多的客户。最后,ChanXpress将开发一种Herg-Lite试剂盒,其中包括细胞系、试剂和仪器选项,以便客户能够在自己的设施中进行这种分析。HERG-Lite结合了快速、低成本、高通量和全面的HERG可靠性预测,使其成为药物开发过程早期HERG可靠性筛查的首选检测方法。
英文摘要
DESCRIPTION (provided by applicant): Ion channels comprise 10-20 percent of known drug targets for diseases including cardiac arrhythmias, stroke, hypertension, heart failure, asthma, cystic fibrosis, epilepsy, migraine, mental disorders, muscular dystrophy, and cancer. While ion channels provide important therapeutic targets, they are often the focal point of unwanted drug interactions leading to potentially serious side effects. The cardiac potassium channel hERG is the most common target of undesired drug interactions; block of hERG can predispose individuals to cardiac arrhythmias, long QT syndrome, and sudden cardiac death. The FDA recommends that all drugs being considered for investigational new drug applications (IND) be tested for their effects on the hERG potassium channel in preclinical studies. Due to the increasing costs of drug development, it is crucial that pharmaceutical companies test their compounds for hERG liability at early stages in the process. Recent evidence indicates that drug-induced hERG liability can arise not just from direct block of the channel, but by inhibiting the movement of the hERG channel from its intracellular site of synthesis to the cell surface. This trafficking inhibition results in fewer functional channels at the cell surface. Arsenic trioxide and pentamidine, both of which are in clinical use today, act in this fashion and have been linked to long QT syndrome. None of the current methods for determining hERG liability are able to detect trafficking inhibitors. ChanXpress, Inc. has developed a novel safety screen for hERG liability that is the most comprehensive available. It detects both channel blockers and trafficking inhibitors using a proprietary technology that monitors surface expression of hERG channels using an antibody-based, chemiluminescent assay. In Phase II, we will compile a hERG liability database of 880 compounds that includes results from hERG-Lite screening along with patch clamp and Western blot data. We will automate the HERG-Lite assay at ChanXpress so that it can be offered to more clients with a higher throughput than is currently available. Finally, ChanXpress will develop a HERG-Lite kit that includes cell line, reagent, and instrumentation options so that clients are able to perform that assay at their own facility. The combination of speed, low cost, high throughput, and comprehensive hERG liability predictions position HERG-Lite as the premier assay for hERG liability screening early in the drug development process.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Novel High Throughput Assay for Ion Channel Modulators
  • 批准号:
    6736717
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2004
  • 负责人:
    Barbara A Wible
  • 依托单位:
A Novel High Throughput Assay for Ion Channel Modulators
  • 批准号:
    6933973
  • 项目类别:
  • 资助金额:
    $65.96万
  • 财政年份:
    2004
  • 负责人:
    Barbara A Wible
  • 依托单位:
A High Throughput Assay for Cancer Drug Cardiotoxicity
  • 批准号:
    6887417
  • 项目类别:
  • 资助金额:
    $24.57万
  • 财政年份:
    2004
  • 负责人:
    Barbara A Wible
  • 依托单位:
NOVEL ACCESSORY PROTEIN MODULATING CARDIAC K+ CHANNELS
  • 批准号:
    6389999
  • 项目类别:
  • 资助金额:
    $25.7万
  • 财政年份:
    1998
  • 负责人:
    Barbara A Wible
  • 依托单位:
海外基金